Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL812418 | 1.00 | CHRNB2 (0.37) | CHRNB2CHRNA7CHRNA4L3MBTL1CHRM5 | |
| SCHEMBL2994601 | 1.00 | CHRNB2 (0.37) | CHRNB2CHRNA7CHRNA4L3MBTL1CHRM5 | |
| SCHEMBL2998727 | 0.98 | CHRNB2 (0.36) | CHRNB2CHRNA7CHRNA4L3MBTL1CHRM5 | |
| SCHEMBL2996449 | 0.98 | CHRNB2 (0.36) | CHRNB2CHRNA7CHRNA4L3MBTL1CHRM5 | |
| SCHEMBL4628774 | 0.98 | CHRNB2 (0.36) | CHRNB2CHRNA7CHRNA4L3MBTL1CHRM5 | |
| SCHEMBL2991651 | 0.98 | CHRNB2 (0.36) | CHRNB2CHRNA7CHRNA4L3MBTL1CHRM5 | |
| SCHEMBL2996446 | 0.98 | CHRNB2 (0.36) | CHRNB2CHRNA7CHRNA4L3MBTL1CHRM5 | |
| SCHEMBL2998728 | 0.98 | CHRNB2 (0.36) | CHRNB2CHRNA7CHRNA4L3MBTL1CHRM5 | |
| SCHEMBL943172 | 0.94 | MEN1 (0.39) | CHRNB2CHRNA7CHRNA4L3MBTL1PARP1 | |
| Proline SCHEMBL28261914 | 0.86 | GRIN2D (0.35) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119431219-A | Chiral 3-hydroxy-4-fluoropiperidine derivative and synthesis method thereof | 诚达药业股份有限公司 | 2025-02-14 | — | — | CN | claimed |
| EP-3688007-B1 | BIOCONJUGATION OF POLYPEPTIDES | UNIV YORK (GB) | 2024-07-31 | — | — | EP | claimed |
| EP-3688007-A1 | BIOCONJUGATION OF POLYPEPTIDES | The University of York (GB) | 2020-08-05 | — | — | EP | claimed |
| WO-2019063958-A1 | BIOCONJUGATION OF POLYPEPTIDES | THE UNIVERSITY OF YORK (GB) | 2019-04-04 | — | — | WO | claimed |
| CN-101228153-A | Preparation of terazole derivatives | NOVARTIS AG (CH) | 2008-07-23 | — | — | CN | claimed |
| WO-2025073956-A1 | STING ANTAGONIST COMPOUNDS | SULIS THERAPEUTICS APS (DK) | 2025-04-10 | — | — | WO | disclosed |
| EP-4534147-A1 | STING ANTAGONIST COMPOUNDS | Sulis Therapeutics ApS (DK) | 2025-04-09 | — | — | EP | disclosed |
| CN-119431219-A | Chiral 3-hydroxy-4-fluoropiperidine derivative and synthesis method thereof | 诚达药业股份有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-116102537-B | Quinolinone derivative and preparation method and application thereof | 四川大学 | 2024-10-01 | — | — | CN | disclosed |
| EP-3688007-B1 | BIOCONJUGATION OF POLYPEPTIDES | UNIV YORK (GB) | 2024-07-31 | — | — | EP | disclosed |
| US-11897917-B2 | Bioconjugation of polypeptides | THE UNIVERSITY OF YORK (GB) | 2024-02-13 | — | — | US | disclosed |
| EP-3421454-B9 | PIPERIDINE DERIVATIVE | OTSUKA PHARMA CO LTD (JP) | 2023-08-09 | — | — | EP | disclosed |
| EP-1907378-A1 | PREPARATION OF TERAZOLE DERIVATIVES | Novartis AG (CH) | 2008-04-09 | — | — | EP | disclosed |
| US-20070055081-A1 | Processes for production of alpha-aminooxyketones and alpha-hydroxyketones | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2007-03-08 | — | — | US | disclosed |
| US-20070055081-A1 | Processes for production of alpha-aminooxyketones and alpha-hydroxyketones | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2007-03-08 | — | — | US | disclosed |
| US-20070037973-A1 | reacting a cyclic alpha , beta -unsaturated ketone compound with a nitroso compound in the presence of a proline-based catalyst to provide 7-Phenyl-6-oxa-7-aza-bicyclo[3.2.2]nonan-9-one or derivatives; catalytic asymmetric O-nitroso Aldol/Michael reaction | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2007-02-15 | — | — | US | disclosed |
| US-20070037973-A1 | reacting a cyclic alpha , beta -unsaturated ketone compound with a nitroso compound in the presence of a proline-based catalyst to provide 7-Phenyl-6-oxa-7-aza-bicyclo[3.2.2]nonan-9-one or derivatives; catalytic asymmetric O-nitroso Aldol/Michael reaction | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2007-02-15 | — | — | US | disclosed |
| WO-2007009716-A1 | PREPARATION OF TERAZOLE DERIVATIVES | NOVARTIS AG (CH) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007009716-A1 | PREPARATION OF TERAZOLE DERIVATIVES | NOVARTIS AG (CH) | 2007-01-25 | — | — | WO | disclosed |
| WO-2006023720-A2 | REACTIONS OF ENOLIZABLE A-AMINO ALDEHYDES OR KETONES TO FORM AMINE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037973-A1 | reacting a cyclic alpha , beta -unsaturated ketone compound with a nitroso compound in the presence of a proline-based catalyst to provide 7-Phenyl-6-oxa-7-aza-bicyclo[3.2.2]nonan-9-one or derivatives; catalytic asymmetric O-nitroso Aldol/Michael reaction | XDH, PDXK, AOX1 | CHRNB2 1773/4885CHRNA7 1001/4885CHRNA4 1417/4885 |
| US-20070055081-A1 | Processes for production of alpha-aminooxyketones and alpha-hydroxyketones | KHK, HCCS, XDH | CHRNB2 3672/4885CHRNA7 2768/4885CHRNA4 3082/4885 |
| US-11897917-B2 | Bioconjugation of polypeptides | PTMS, EPCAM, IAPP | CHRNB2 2573/4885CHRNA7 4158/4885CHRNA4 4032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.